StevenMHorwitzMD

Hematologic Oncology

Assistant Professor, Medicine, Weill Cornell Medical College

Overview of Dr. Horwitz

Dr. Steven Horwitz is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Hospital for Cancer and allied Diseases. He received his medical degree from Case Western Reserve University School of Medicine and has been in practice 24 years. Dr. Horwitz accepts several types of health insurance, listed below. He is one of 494 doctors at Memorial Sloan Kettering Cancer Center and one of 90 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Oncology. He has more than 100 publications and over 500 citings.

Office
1275 York Ave
New York, NY 10065
Book by Phone+1(385) 207-2096

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1997 - 1999
University of RochesterResidency, Internal Medicine, 1993 - 1996
Case Western Reserve University School of MedicineClass of 1993

Certifications & Licensure

CA State Medical License 1997 - Present
FL State Medical License 2021 - Present
CT State Medical License 2024 - 2025
NJ State Medical License 2019 - 2025
NY State Medical License 1995 - 2025
PA State Medical License 2022 - 2024
NC State Medical License 2020 - 2022
OK State Medical License 2020 - 2021
American Board of Internal Medicine Medical Oncology
Join now to see all

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2010-2014
Top Doctors: New York Metro Area Castle Connolly, 2010-2014
America's Top Doctors for Cancer Castle Connolly, 2009-2013

Clinical Trials

MDX-060 Monoclonal Antibody in Treating Patients With Refractory or Relapsed Lymphoma Start of enrollment: 2003 Jan 01
Completed
Phase 1, Phase 2
Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell Lymphoma Start of enrollment: 2005 Nov 01
Completed
Phase 2
Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment Start of enrollment: 2006 Jun 27
Completed
Phase 1, Phase 2
T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma Start of enrollment: 2006 Sep 01
Completed
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma Start of enrollment: 2011 Aug 01
Completed
Phase 2
Communication Skills Intervention to Promote Transition Into Survivorship Start of enrollment: 2011 Nov 01
Active, not recruiting
KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL) Start of enrollment: 2012 Jun 01
Completed
Phase 2
Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma Start of enrollment: 2012 Dec 01
Completed
Phase 1, Phase 2
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Start of enrollment: 2013 Jan 31
Completed
Phase 3
Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma Start of enrollment: 2017 Mar 08
Recruiting
Phase 1, Phase 2
Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma. Start of enrollment: 2018 Oct 14
Recruiting
Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome Start of enrollment: 2021 Oct 01
Recruiting
Phase 2
Roles: Contact
A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression Start of enrollment: 2020 Nov 12
Active, not recruiting
Phase 2
Roles: Principal Investigator, Contact
A Registry for People With T-cell Lymphoma Start of enrollment: 2023 Jul 27
Recruiting
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

334 citations
Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study
Owen A. O'Connor, Steven M. Horwitz, Tamas Masszi, Achiel Van Hoof, Peter de Nully Brown
Journal of Clinical Oncology. 2015-06-22
174 citations
Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies.
Ian W. Flinn, Susan O'Brien, Brad S. Kahl, Manish Patel, Yasuhiro Oki
Blood. 2018-02-22
85 citations
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.
Alison J. Moskowitz, Gunjan L. Shah, Heiko Schöder, Nivetha Ganesan, Esther Drill
Journal of Clinical Oncology. 2021-06-25

Journal Articles

Pembrolizumab in Mycosis Fungoides and Sézary Syndrome: Updated Results of the CITN Multicenter Phase 2 Study
Michael S Khodadoust, Pierluigi Porcu, Francine Foss, Andrei R Shustov, Satish Shanbhag, Lubomir Sokol, Steven M Horwitz, Elad Sharon, European Journal of Cancer
TCR‐Δ Expression and Γδ+ T‐Cell Infiltrates in Primary Cutaneous Gamma‐Delta T‐Cell Lymphoma and Other Cutaneous T‐Cell Lymphoproliferative Disorders
Patricia Myskowski, Melissa Pulitzer, Steven Horwitz, Meenal Kheterpal, Shamir Geller, Allison Moskowitz, Histopathology

Abstracts/Posters

Expectant Management of Extranodal Marginal Zone Lymphoma of Bronchial-Associated Lymphoid Tissue (BALT)
Steven M. Horwitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Genomic Profiling of Mantle Cell Lymphoma Suggests Poor-Risk Profile Is Present at Diagnosis and Does Not Arise By Tumor Evolution
Steven M. Horwitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Phase 1/1b Dose-Escalation Trial Evaluating Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects with Relapsed/Refractory T-Cell Lymphoma
Steven M. Horwitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin As Pre-Transplant Salvage for Classical Hodgkin Lymphoma
Steven M. Horwitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed ...
Steven M. Horwitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Contemporary Outcomes in HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: Single-Institution Experience
Steven M. Horwitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Characteristics, Treatment Patterns, and Outcomes in Primary Cutaneous Gamma Delta T Cell Lymphoma (PCGDTCL): A Real World Multi-Institutional Analysis of a Rare Malig...
Steven M. Horwitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma
Steven M. Horwitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Incidence of Delayed Seromas and Related Risk of Bia-ALCL in a Cohort of 3521 Breast Cancer Women with Textured Implants Prospectively Followed Long Term
Steven M. Horwitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Co...
Steven M. Horwitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Belinostat Induces High Overall Response Rate (ORR) in Patients with Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL)
Steven M. Horwitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Retrospective Analysis of Gemcitabine and Oxaliplatin (GemOx)-Based Treatment in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Steven M. Horwitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
Steven M. Horwitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Central Nervous System Prophylaxis with High-Dose Intravenous Methotrexate or Intrathecal Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma and High-Risk of ...
Steven M. Horwitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Phase 1/1b Dose-Escalation Trial Evaluating Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects with Relapsed/Refractory T-Cell Lymphoma
Steven M. Horwitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Dose Optimization of Duvelisib in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Selection of Regimen for the Dose-Expan...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
New Directions in Treating Peripheral T-Cell Lymphomas: Expert Guidance and Case Discussions
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Superior Clinical Benefit of Brentuximab Vedotin in Mycosis Fungoides Versus Physician's Choice Irrespective of CD30 Level or Large Cell Transformation Status in the P...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Efficacy of Mogamulizumab By Prior Systemic Therapy in Patients with Previously Treated Cutaneous T-Cell Lymphoma: Post Hoc Analysis from the Phase 3 Mavoric Study
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Circulating Lymphoma Cells in Mycosis Fungoides/Sezary Syndrome Show Heterogeneity of the Cell-of-Origin and Variable PD-1 Expression By Flow Cytometric Analysis
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Preliminary Results of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Two Phase IIa Dose Expansion Cohorts in Relapsed/Refractory TP53 Wild-Type ...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
The PRIMO study: A phase 2 study of duvelisib efficacy and safety in patients with relapsed or refractory peripheral t-cell lymphoma (PTCL).
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Join now to see all

Authored Content

Pembrolizumab in Mycosis Fungoides and Sézary Syndrome: Updated Results of the CITN Multicenter Phase 2 StudyAugust 2018

Press Mentions

Did the Covid Jab Make a Famous Doctor’s Cancer WORSE?September 30th, 2022
New Combo Therapy for Breast Implant–Associated LymphomaJanuary 18th, 2022
$Verastem Oncology to Present Phase 2 PRIMO Study Data Evaluating Duvelisib in Relapsed or Refractory Peripheral T-cell Lymphoma at the American Society of Hematology 2019 Annual Meeting$
Verastem Oncology to Present Phase 2 PRIMO Study Data Evaluating Duvelisib in Relapsed or Refractory Peripheral T-cell Lymphoma at the American Society of Hematology 2019 Annual MeetingNovember 6th, 2019
Join now to see all

Insurance Accepted

Aetna Choice POS II
Aetna HMO
Anthem Blue Access PPO
Anthem Blue Preferred HMO
BCBS Blue Card PPO
BCBS Illinois PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
GHI PPO
Great West PPO
Humana ChoiceCare Network PPO
Medical Mutual of Ohio SuperMed Plus
Medical Mutual of Ohio SuperMed POS
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
Sagamore Health Plus
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment